RYANODEX (dantrolene sodium) by Eagle Pharmaceuticals is clinical pharmacology in isolated nerve-muscle preparation, dantrolene sodium has been shown to produce relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. First approved in 2014.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
RYANODEX is an intravenous formulation of dantrolene sodium, a skeletal muscle relaxant that works by dissociating excitation-contraction coupling in muscle cells, primarily by interfering with calcium release from the sarcoplasmic reticulum. It is indicated for the acute treatment and prevention of malignant hyperthermia (MH), a rare but life-threatening pharmacogenetic reaction to certain anesthetics. The IV formulation provides rapid onset critical for emergency MH management in the operating room.
At peak lifecycle stage with moderate competitive pressure (30%), indicating a stable but niche specialty market with ongoing commercial support needs.
CLINICAL PHARMACOLOGY In isolated nerve-muscle preparation, dantrolene sodium has been shown to produce relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. In skeletal muscle, dantrolene sodium dissociates…
Worked on RYANODEX at Eagle Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Working on RYANODEX offers deep expertise in rare disease specialty pharma and critical-care prescriber relationships, with career value in regulatory navigation and specialist market development. The niche indication and emergency-use context create distinct career positioning versus broader therapeutic teams, appealing to professionals seeking focused, high-impact specialty work.